Can Pharmacogenetic Variants in TPMT , MTHFR and SLCO1B1 Genes Be Used as Potential Markers of Outcome Prediction in Systemic Sclerosis Patients?

MLA

Jelovac, Marina, et al. “Can Pharmacogenetic Variants in TPMT , MTHFR and SLCO1B1 Genes Be Used as Potential Markers of Outcome Prediction in Systemic Sclerosis Patients?” International Journal of Molecular Sciences, vol. 24, no. 10, May 2023. EBSCOhost, https://doi.org/10.3390/ijms24108538.

APA

Jelovac, M., Kotur, N., Ristivojevic, B., Pavlovic, D., Spasovski, V., Damjanov, N., Pavlovic, S., & Zukic, B. (2023). Can Pharmacogenetic Variants in TPMT , MTHFR and SLCO1B1 Genes Be Used as Potential Markers of Outcome Prediction in Systemic Sclerosis Patients? International Journal of Molecular Sciences, 24(10). https://doi.org/10.3390/ijms24108538

Chicago

Jelovac, Marina, Nikola Kotur, Bojan Ristivojevic, Djordje Pavlovic, Vesna Spasovski, Nemanja Damjanov, Sonja Pavlovic, and Branka Zukic. 2023. “Can Pharmacogenetic Variants in TPMT , MTHFR and SLCO1B1 Genes Be Used as Potential Markers of Outcome Prediction in Systemic Sclerosis Patients?” International Journal of Molecular Sciences 24 (10). doi:10.3390/ijms24108538.